Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.00

by · The Markets Daily

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $56.00.

AGIO has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Bank of America dropped their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Finally, Scotiabank reduced their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a report on Monday, July 28th.

Read Our Latest Report on AGIO

Agios Pharmaceuticals Trading Up 1.2%

Shares of NASDAQ AGIO opened at $36.72 on Friday. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58. The firm’s 50-day moving average is $37.74 and its 200-day moving average is $33.27. The firm has a market capitalization of $2.13 billion, a PE ratio of 3.34 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. As a group, equities research analysts anticipate that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Theodore James Jr. Washburn sold 8,546 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $36.87, for a total transaction of $315,091.02. Following the completion of the transaction, the insider owned 868 shares in the company, valued at approximately $32,003.16. The trade was a 90.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James William Burns sold 2,799 shares of the company’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $93,878.46. Following the completion of the sale, the insider directly owned 28,650 shares of the company’s stock, valued at $960,921. The trade was a 8.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 65,994 shares of company stock worth $2,341,232 over the last ninety days. 4.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in Agios Pharmaceuticals in the 4th quarter valued at $39,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals during the 1st quarter worth about $40,000. CWM LLC raised its stake in shares of Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 499 shares during the period.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Further Reading